XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Parties Transactions (Tables)
 12 Months Ended
Dec. 31, 2023
Related Parties Transactions [Abstract]  
Schedule of Related Parties of the Company with whom Transactions The related parties of the company with whom transactions are reported in these financial statements are as follows:
Name of entity or Individual   Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)   100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
Eugene Jiang   Former President and Chairman
GenePharm Inc. (the “GenePharm”)   Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
The Jiangs   Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst
 
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.
 
Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
 
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.   Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Zhewei Xu   Shareholder of the Company.
BioHopeKing Corporation   Entity controlled by controlling beneficiary shareholder of ABVC
Jaimes Vargas Russman     CEO of AiBtl BioPharma Inc.
Schedule of Accounts Receivable Due From Related Parties Accounts receivable due from related parties consisted of the following as of the periods indicated:
   December 31,   December 31, 
   2023   2022 
GenePharm Inc.  $
-
   $142,225 
Rgene   10,463    615,118 
Total  $10,463   $757,343 
Schedule of Revenue Due From Related Parties - Current Revenue due from related parties consisted of the following as of the periods indicated:
   December 31,   December 31, 
   2023   2022 
Rgene  $2,055   $904,043 
Total  $2,055   $904,043 

 
Schedule of Due From Related Parties - Current Due from related party- Current
   December 31,   December 31, 
   2023   2022 
Rgene  $541,486   $513,819 
BioFirst   206,087    
-
 
Total  $747,573   $513,819 
Schedule of Due From Related Parties - Non Current Due from related parties- Non-current
   December 31,   December 31, 
   2023   2022 
BioFirst (Australia)  $839,983    $ 752,655 
BioHopeKing Corporation   113,516    112,822 
Total   953,499    865,477 
Less: allowance for expected credit losses accounts   (839,983)   - 
Net  $113,516   $865,477 
Schedule of Amount Due to Related Parties Amount due to related parties consisted of the following as of the periods indicated:
   December 31,   December 31, 
   2023   2022 
BioFirst   $
-
   $188,753 
The Jiangs   19,789    19,789 
Due to shareholders   152,382    151,450 
Due to a Director   961    
-
 
Total  $173,132   $359,992